AGX has delivered one of its sharpest weekly rallies in recent memory, jumping 18% to $617.68 — and the most interesting dynamic is that shorts are running for the exit at the same time insiders sold heavily at higher prices just weeks ago.
The short-side retreat is the clearest story in the data this week. Short interest has fallen 13% over the past week to roughly 865,000 shares, or 6.3% of the free float — a meaningful pullback from the recent peak of around 1.13 million shares on July 23. That peak coincided with the tightest borrow conditions of the past month, when availability dropped to 448% of short interest. It has since loosened dramatically to 1,410%, meaning the lending pool is now well-supplied relative to the short position. Borrowing costs remain negligible at 0.45%, confirming there is no squeeze dynamic in play. The ORTEX short score has eased from 52 on July 23 to 42 this week — a 10-point drop that reflects the combination of falling short interest and improving price momentum. Shorts aren't being squeezed so much as they are quietly stepping back.
Options positioning adds some nuance to that picture. The put/call ratio runs at 1.46, above its 20-day average of 1.40, but only modestly so — a z-score of 0.38 suggests this is well within normal territory. What is more telling is the step-change that occurred around July 17-20, when the PCR jumped from roughly 1.07 to 1.46 and has stayed there. That shift tracks almost exactly with the period when short interest was peaking and the stock was under pressure. Options traders moved more defensively into the dip, and the hedges haven't fully unwound despite this week's recovery.
The Street picture is complicated by stale data. The most recent analyst action on record is Lake Street's June 5 target raise to $600 — still a Hold — which now sits below the current price of $617. The mean analyst target across coverage is $679.80, implying modest upside from here, but with a $518 Goldman Buy target and a $600 Lake Street Hold target both lagging where the stock is trading, it is fair to say the Street has not fully kept pace with AGX's move. JP Morgan upgraded to Overweight back in late March with a $550 target; the stock has since run well past that level. On valuation, the trailing PE has compressed roughly 21% over the past 30 days to 39x as the stock pulled back from its June highs near $760, and the price-to-book has shed nearly 2.9 turns to 10.6x over the same period — the stock is cheaper than it was, but not cheap.
The insider picture is worth flagging. In mid-to-late June, when AGX was trading near $700-$760, there was a concentrated wave of selling across multiple levels of the organization. The subsidiary Chairman sold 50,000 shares across two transactions for over $36 million. The CEO sold nearly 1,900 shares at $707. The CFO trimmed twice. Several independent directors followed. Net insider activity over 90 days amounts to roughly $87.6 million of net selling. The stock has since pulled back about 19% from those June highs, suggesting the insiders who sold near $730-$760 are sitting on gains relative to current levels. A director sold again on July 31 at $579, adding to the pattern.
For peer context, AGX's 18% weekly gain stands out sharply. PWR rose 18% on the week and EME added 16%, suggesting a broad sector re-rating rather than an AGX-specific catalyst. MTZ actually fell 13% on the week, highlighting how divergent outcomes can be even within the same group. IESC surged 40% — the outlier of the peer set. The sector tailwind appears real, but AGX is moving in line with the stronger names rather than leading the group.
The next scheduled event is Q1 earnings on September 3. The last print in June saw a modest 1.2% day-one gain but a 9% five-day fade — a pattern worth keeping in mind as the stock approaches resistance near analyst target prices with a 13% monthly decline still fresh in the data.
See the live data behind this article on ORTEX.
Open AGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
